End-of-day quote
Moscow Micex - RTS
23:00:00 07/07/2022 BST
|
5-day change
|
1st Jan Change
|
4.505
RUB
|
+10.15%
|
|
-.--%
|
-.--%
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Capitalization
1 |
3,612
|
1,680
|
1,249
|
2,062
|
1,689
|
1,356
|
Enterprise Value (EV)
1 |
3,465
|
2,012
|
1,623
|
2,675
|
2,382
|
2,092
|
P/E ratio
|
-1.31
x
|
-4.01
x
|
-0.69
x
|
-3.93
x
|
-2.42
x
|
-6.53
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
4.99
x
|
4.81
x
|
4.29
x
|
5.55
x
|
3.85
x
|
3.57
x
|
EV / Revenue
|
4.79
x
|
5.76
x
|
5.58
x
|
7.2
x
|
5.43
x
|
5.51
x
|
EV / EBITDA
|
-3.59
x
|
-15.2
x
|
-8.46
x
|
-26
x
|
-12.2
x
|
-19.7
x
|
EV / FCF
|
-60.6
x
|
-43.1
x
|
-25
x
|
-7.91
x
|
26.9
x
|
99.7
x
|
FCF Yield
|
-1.65%
|
-2.32%
|
-4%
|
-12.6%
|
3.72%
|
1%
|
Price to Book
|
1.71
x
|
0.48
x
|
0.92
x
|
2.03
x
|
4.89
x
|
11.2
x
|
Nbr of stocks (in thousands)
|
301,011
|
301,011
|
301,011
|
301,011
|
301,011
|
301,011
|
Reference price
2 |
12.00
|
5.580
|
4.150
|
6.850
|
5.610
|
4.505
|
Announcement Date
|
27/07/18
|
01/03/21
|
01/03/21
|
30/04/21
|
28/04/22
|
19/05/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
1 |
723.5
|
349.4
|
291.1
|
371.7
|
438.3
|
379.7
|
EBITDA
1 |
-964.6
|
-132.4
|
-191.8
|
-103
|
-195.6
|
-106.1
|
EBIT
1 |
-1,015
|
-187
|
-217.7
|
-147.4
|
-227.6
|
-126
|
Operating Margin
|
-140.33%
|
-53.52%
|
-74.8%
|
-39.65%
|
-51.91%
|
-33.18%
|
Earnings before Tax (EBT)
1 |
-2,843
|
-550.7
|
-2,029
|
-527.2
|
-733.4
|
-208.7
|
Net income
1 |
-2,522
|
-417.7
|
-1,812
|
-524.8
|
-697.6
|
-207.5
|
Net margin
|
-348.6%
|
-119.55%
|
-622.45%
|
-141.21%
|
-159.14%
|
-54.65%
|
EPS
2 |
-9.134
|
-1.390
|
-6.020
|
-1.744
|
-2.320
|
-0.6900
|
Free Cash Flow
1 |
-57.23
|
-46.71
|
-64.91
|
-338.3
|
88.65
|
20.98
|
FCF margin
|
-7.91%
|
-13.37%
|
-22.3%
|
-91.03%
|
20.22%
|
5.53%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
27/07/18
|
01/03/21
|
01/03/21
|
30/04/21
|
28/04/22
|
19/05/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
-
|
333
|
374
|
613
|
693
|
736
|
Net Cash position
1 |
147
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-2.512
x
|
-1.948
x
|
-5.955
x
|
-3.543
x
|
-6.941
x
|
Free Cash Flow
1 |
-57.2
|
-46.7
|
-64.9
|
-338
|
88.6
|
21
|
ROE (net income / shareholders' equity)
|
-82%
|
-10.6%
|
-74.9%
|
-44.1%
|
-103%
|
-89%
|
ROA (Net income/ Total Assets)
|
-13.5%
|
-2.33%
|
-3.9%
|
-4.11%
|
-8.18%
|
-5.7%
|
Assets
1 |
18,683
|
17,948
|
46,447
|
12,759
|
8,529
|
3,642
|
Book Value Per Share
2 |
7.010
|
11.50
|
4.530
|
3.370
|
1.150
|
0.4000
|
Cash Flow per Share
2 |
1.300
|
0.0200
|
0.2200
|
0.0300
|
0.0500
|
0.0300
|
Capex
1 |
9.45
|
19.4
|
14.5
|
9.68
|
0.28
|
3.47
|
Capex / Sales
|
1.31%
|
5.54%
|
4.98%
|
2.61%
|
0.06%
|
0.91%
|
Announcement Date
|
27/07/18
|
01/03/21
|
01/03/21
|
30/04/21
|
28/04/22
|
19/05/23
|
|
1st Jan change
|
Capi.
|
---|
| -.--% | 14.93M | | +32.09% | 694B | | +29.39% | 593B | | -1.34% | 371B | | +20.34% | 331B | | +7.39% | 290B | | +14.25% | 239B | | -3.03% | 209B | | +10.02% | 209B | | +8.49% | 169B |
Other Pharmaceuticals
|